Why the study?
Does percutaneous transluminal coronary angioplasty stimulate platelet and prostaglandin activity in patients with coronary artery disease?
Does percutaneous transluminal coronary angioplasty stimulate platelet and prostaglandin activity in patients with coronary artery disease?
PTCA does not appear to acutely alter arachidonic acid metabolism or platelet activity in patients with coronary artery disease.
Answers are grounded in this paper and cite their sources.
PTCA may not acutely alter platelet activity in CAD; leaves open whether baseline coronary sinus PF4 elevation influences outcomes or merits intervention.
Platelet function and prostaglandin activity were evaluated in nine patients with coronary artery disease undergoing percutaneous left anterior descending coronary artery angioplasty (PTCA) and compared to nine normal controls. Transcoronary measurements (arterial-coronary sinus) of platelet counts, mean platelet volume, platelet factor 4 (PF4), beta thromboglobulin, thromboxane (B2), and 6-keto-PGF 1 alpha were made. When compared to normal controls, the patients with coronary artery disease had higher circulating baseline levels of PF4 in the coronary sinus. There was no transcardiac production of any factor at baseline or immediately after infusion of nitroglycerin or performance of PTCA. These results suggest that PTCA does not grossly alter arachidonic acid metabolism or platelet activity.
No takes yet. Share an insight, caveat, or question.
Stine et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: